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ABSTRACT
Introduction: The leishmaniases represent a group of parasitic diseases caused by infection with one of 
several species of Leishmania parasites. Disease presentation varies because of differences in parasite 
and host genetics and may be influenced by additional factors such as host nutritional status or co- 
infection. Studies in experimental models of Leishmania infection, vaccination of companion animals 
and human epidemiological data suggest that many forms of leishmaniasis could be prevented by 
vaccination, but no vaccines are currently available for human use.
Areas covered: We describe some of the existing roadblocks to the development and implementation 
of an effective leishmaniasis vaccine, based on a review of recent literature found on PubMed, BioRxiv 
and MedRxiv. In addition to discussing scientific unknowns that hinder vaccine candidate identification 
and selection, we explore gaps in knowledge regarding the commercial and public health value 
propositions underpinning vaccine development and provide a route map for future research and 
advocacy.
Expert opinion: Despite significant progress, leishmaniasis vaccine development remains hindered by 
significant gaps in understanding that span the vaccine development pipeline. Increased coordination 
and adoption of a more holistic view to vaccine development will be required to ensure more rapid 
progress in the years ahead.
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1. Introduction
Leishmaniasis is endemic in 95 countries worldwide and the 
cause of significant morbidity and mortality. The notion that 
prevention of leishmaniasis can be achieved through vaccina-
tion is supported by a significant body of experimental and 
epidemiological data, but currently no vaccine exists for 
human use. This review addressed some of the major impedi-
ments to the development of vaccines for human 
leishmaniasis.
1.1. Leishmaniasis: the clinical and public health context
The leishmaniases are a collection of globally important 
neglected diseases caused by several species of the protozoan 
parasite Leishmania. It is estimated that up to 1 billion people 
are at risk of infection [1,2]. Based on the most recent data, 
between 498,000 and 862,000 new cases of all forms of leish-
maniasis occur each year resulting in up to 18,700 deaths and 
1.6 million disability adjusted life years (DALYs) lost [3]. 
Transmitted by the bite of phlebotomine sand flies, the leish-
maniases disproportionately affect populations in low- and 
middle-income countries (LMICs). In addition to the obvious 
effect on health during clinical disease, there is a growing 
appreciation of the impact of long-term sequelae associated 
with different forms of leishmaniasis, notably on mental health 
[4]. For example, the DALY burden associated with cutaneous 
leishmaniasis was estimated to be up to seven-fold higher 
when accounting for major depressive disorder [5]. Similarly, 
leishmaniasis may have major impacts on economic prosperity 
at the individual and community level, through reducing an 
infected individual’s ability to work and the caregiving require-
ments that fall on wider families and communities [6]. In one 
study in Sudan, 75% of households were reported to incur 
catastrophic out-of-pocket costs amounting to up to 40% of 
annual income when a family member required treatment for 
visceral leishmaniasis [7].
Underpinning the geographic distribution and varied clin-
ical presentation of the leishmaniases is a complex evolution-
ary relationship between vector, parasite and host [8]. At least 
19 species of sand fly are capable of supporting the develop-
ment of Leishmania and have been incriminated as vectors, 
and human leishmaniasis has been attributed to at least 20 
species of parasite belonging to two sub genera, Leishmania 
(Leishmania) and Leishmania (Viannia) [8]. Human genetics 
almost certainly plays a role in determining disease outcome, 
though well-evidenced examples are few and far between [9]. 
Other factors such as malnutrition [10], co-infection [11] and 
socio-economic status [12] also contribute, with leishmaniasis 
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described as reflecting a vicious cycle of poverty and infec-
tion [13].
Clinically, the leishmaniases may be loosely sub-divided 
into tegumentary leishmaniasis (affecting the skin and muco-
sae) and visceral leishmaniasis, involving the systemic organ 
systems. With an annual reported incidence of over 600,000 
new cases across 55 countries, the tegumentary leishmaniases 
represent the greatest disease burden. These include localized 
cutaneous leishmaniasis (LCL), disseminated cutaneous leish-
maniasis (DL), diffuse (anergic) cutaneous leishmaniasis (DCL), 
mucocutaneous leishmaniasis (MCL) and post-kala-azar dermal 
leishmaniasis (PKDL). Each is typically but not uniquely asso-
ciated with specific parasite species. For example, L. major and 
L. tropica are responsible for most LCL in Africa, Asia, and the 
Middle East, whereas LCL in the Americas is associated with 
L. mexicana, L. peruviana, L (V.) guyanensis and L. (V.) brazilien-
sis, among others. Associations between parasite species and 
disease presentation are however not prescriptive. In Ethiopia, 
the full spectrum of tegumentary disease is associated with 
infection by L. ethiopica and inter-species hybrids are being 
discovered in many regions of the world [14,15], further com-
plicating this picture.
Brazil, East Africa and South Asia carry the burden of visc-
eral leishmaniasis, a disease that is invariably fatal in the 
absence of treatment and responsible for most Leishmania- 
attributable deaths [2]. PKDL is a chronic stigmatizing skin 
condition that develops in 5–30% of patients successfully 
treated for VL and affects quality of life particularly in young 
adults and females [16]. PKDL patients also provide a reservoir 
for Leishmania transmission and represent a significant risk to 
VL elimination programs [17,18].
1.2. Leishmaniasis – the life cycle and immune control of 
infection
Infection with Leishmania parasites is initiated during sand fly 
bite, with regurgitation of metacyclic promastigotes into the 
host dermis. From a holistic standpoint, transmission involves 
not only the transfer of parasites, but also reflects the biolo-
gical properties of sand fly-derived proteins, parasite-excreted 
phosphoglycans and components of the sand fly microbiota 
[19]. Collectively, this microenvironment is permissible to 
infection of a variety of host cells including neutrophils, mono-
cytes, tissue resident dermal macrophages and stromal cells. 
Whilst conversion to intracellular amastigotes may occur in 
many cells types, replication of amastigotes is more commonly 
associated with parasitism of mononuclear phagocytes where 
it occurs within a prescribed parasitophorous vacuole/phago-
lysosome [20]. This intracellular lifestyle largely dictates the 
nature and efficacy of the ensuing acquired immune response. 
Whilst B cells are activated and can produce copious quanti-
ties of antibodies that have utility in diagnosis, these are 
thought to be ineffective at killing intracellular parasites. 
A role for antibodies in limiting cell to cell transfer and para-
site dissemination has not however been formally disproved. 
Antibodies may also facilitate killing of infected cells through 
antibody-dependent cellular cytotoxicity (ADCC), though 
again this has not been formally demonstrated. In contrast, 
several decades of research in experimental models and in 
patients has firmly established the role of T cell mediated 
immunity in determining the outcome of natural infection 
and as the primary mediator of vaccine-induced protection, 
at least in animal models. Tcell-derived cytokines (notably 
interferon-γ; IFNγ) serve to enhance the innate leishmanicidal 
properties of macrophages and thus promote cure, whereas 
disease progression is associated with cytokines that either 
directly inhibit macrophage leishmanicidal activity or skew 
T-cell differentiation away from IFNγ production. Regulatory 
cytokines, notably interleukin (IL)-10 produced by T cells and 
other cells including macrophages and B cells, play an impor-
tant role in fine-tuning these responses and maintaining 
a balance between immunity and immunopathology. 
Cytotoxicity focused on infected macrophages whose function 
has been depressed by intracellular parasitism may allow pha-
gocytosis by cells with greater leishmanicidal activity, provid-
ing an alternate host protective mechanism. Although both 
CD4+ and CD8+ T cells play a role in these host protective 
pathways, both can also contribute to pathology and most 
aspects of clinical disease are immunopathologic in nature. 
The immunology and immunopathology of leishmaniasis are 
reviewed in detail elsewhere [21–23].
1.3. Vaccines for leishmaniasis – current state of the art
There have been many recent reviews of leishmaniasis vaccine 
development [21,24–30] and only a summary is warranted 
here. First-generation vaccines, comprising whole killed 
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Leishmania promastigotes, usually adjuvanted with M. bovis 
BCG and/or Alum, had been shown to have some therapeutic 
promise, but have not been developed further. However, pro-
phylactic vaccine trials in humans have proved disappointing, 
with a recent meta-analysis of clinical data finding evidence of 
immunogenicity but not protection [27]. A new generation of 
live genetically attenuated (GA) vaccines for leishmaniasis 
have now been developed, showing great promise in experi-
mental models [31], including cross protection by a L. major 
centrin−/− vaccine against vector-transmitted L. donovani 
infection in hamsters [32]. These are discussed more fully 
elsewhere [33]. Second-generation subunit vaccines (including 
peptides and proteins in a variety of adjuvant and delivery 
systems [34];) have shown promise in various experimental 
models of cutaneous and visceral leishmaniasis. Complete 
protection (e.g. failure of lesion development or lack of viscer-
alisation) has rarely been demonstrated, however, and few 
such candidates have progressed to human clinical trial. 
Notable in this regard are various incarnations of a poly- 
protein fusion adjuvanted with an oil emulsion developed by 
the Infectious Diseases Research Institute [35]. Subunit vac-
cines for canine VL have shown sufficient evidence of protec-
tion to warrant licensure [36], but their formulations are 
unsuitable for human use. Third generation, or DNA-based 
vaccines have been shown to be effective in rodent and 
simian models [37] and one, the adenovirus-based vaccine 
ChAd63-KH, has been shown to be safe and immunogenic in 
healthy UK volunteers [38] and in Sudanese patients with 
persistent PKDL [39]. The results of a randomized, placebo- 
controlled efficacy trial to assess the therapeutic benefit of 
vaccination with ChAd63-KH in PKDL patients are expected in 
2022. mRNA vaccines, which have risen to the fore as a result 
of the COVID-19 pandemic [40], have yet to be fully explored 
in the context of leishmaniasis, with only in vitro studies on 
candidate antigen expression reported to date [41]. 
Nevertheless, as for vaccine development for malaria and 
other NTDs [42,43], adoption of this technology within leish-
maniasis vaccine development programs is likely to be rapid.
2. Roadblocks along the path to vaccine 
development
2.1. The breadth of the challenge
Developing any new vaccine is a complex, multistep process 
fraught with scientific and practical challenges many of which 
are amplified in the context of vaccines for neglected diseases 
[44,45]. These challenges or roadblocks may be evident at 
various stages along the conventional linear ‘laboratory to 
clinic’ development process, but also arise from knowledge 
gaps that negatively impact on rational vaccine design, man-
ufacture, deployment, and perception of public health value 
(Figure 1). Here, we focus on identifying key roadblocks to 
leishmaniasis vaccine development across this broad spectrum 
of inter-disciplinary activities. We have taken a disease- and 
vaccine-agnostic approach to the discussion, as many of the 
principles apply equally to vaccines targeting VL and CL and in 
either a prophylactic or a therapeutic setting. Where there are 
specific considerations, these have been noted.
2.2. Candidate antigen selection
Typically, candidate vaccine antigens are identified by: i) tar-
geted antigen discovery using immune cells or serum to 
directly identify antigens recognized following parasite expo-
sure [24,30], ii) reverse vaccinology, employing bioinformatic 
analysis of Leishmania proteome or genome data [46–48], iii) 
reverse vaccinology based on an understanding of human 
genetic control of leishmaniasis and peptide elution from 
HLA molecules [49], iv) identifying sand fly salivary compo-
nents that facilitate infection [50,51], and v) serendipity, arising 
as an offshoot of fundamental research on parasite biology 
and/or the host–pathogen interaction. The latter reflects 
a major knowledge gap in the foundational step of vaccine 
antigen selection, namely that we have few if any bona fide 
virulence factors identified in Leishmania. Best characterized 
are the surface lipophosphoglycan (a challenging glycoconju-
gate for vaccine development [52]), the protease gp63 [53] 
and a variety of components of the parasite secreted via 
exosomes [54]. As if by design, Leishmania does not possess 
a single ligand responsible for infection of phagocytes, lacks 
secretory organelles delivering invasion-related proteins, does 
not deliver virulence factors via dedicated pathways and does 
not have a single ‘toxin’ responsible for disease. Thus, key 
elements associated with successful vaccine development for 
other pathogens are absent. Future exploration of the abun-
dant hypothetical proteins encoded in the Leishmania gen-
ome may help identify mechanisms of virulence more directly 
targetable by vaccines and a paradigm shift in how vaccine 
antigens are selected. An alternative explanation for the 
plethora of candidate antigens showing success in animal 
models may be that once triggered, even by limited antigen 
release from a few dead parasites, vaccine-induced protection 
is then mediated relatively nonspecifically, reliant on promis-
cuous killing of parasites by activated macrophages. 
Generation of parasites deficient in select vaccine antigens 
by CRISPR/cas9 engineering provides a route to test this 
hypothesis. Novel methods for epitope selection based on 
high throughput T cell receptor sequencing are now available 
[55] and will likely provide an even more granular view of 
human antigen recognition across the leishmaniasis disease 
spectrum and after cure. Whilst small-scale pilot studies will 
provide initial insights, appropriately designed epidemiologi-
cal studies will be required to link such data to disease out-
come and control for confounding factors affecting immune 
recognition. As parasite immune evasion strategies have been 
honed by their evolution in response to naturally induced 
immune responses, due consideration should also be given 
to identifying novel pathways of immunity that can be 
induced by vaccination without an over-reliance on vaccines 
trying to mimic natural immunity.
Given the background of so many vaccination studies in 
animals and with so many candidate antigens (albeit many 
selected on relatively weak evidence), it is pertinent to ask 
whether more are needed. Do we already have a sufficient 
armory of candidate antigens and what is lacking is the 
capacity to evaluate these across different platforms and in 
models that are sufficiently predictive of human response, or 
indeed in humans themselves? These types of studies 
EXPERT REVIEW OF VACCINES 3
(involving harmonized protocols and end points, potentially 
complex models of vector transmission, IP discussions related 
to mixing of platform technologies and the like) are challen-
ging for any single organization to conduct, particularly if 
their core business is discovery science. Or do we have to re- 
set and apply more rigorous selection criteria for candidate 
antigens based on large-scale interrogation of human 
immune responses. Either way, the development of 
a comprehensive framework for identifying and evaluating 
existing and emerging candidate antigens may facilitate 
progress in this regard, e.g. following the model of CEPI 
(https://cepi.net/get_involved/cfps) and/or the Solidarity 
study for COVID-19 treatments (https://www.who.int/emer 
gencies/diseases/novel-coronavirus-2019/global-research-on- 
novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid 
-19-treatments). Such a framework could also incorporate 
evidence of target disease burden and vaccine demand as 
selection criteria given that, as discussed below, these factors 
will ultimately determine the public health and commercial 
viability of a vaccine.
Figure 1. Factors influencing the development of leishmaniasis vaccines.
The central column depicts the linear development process from discovery science through preclinical models, manufacturing and into human trials. Not depicted for clarity is the 
significant level of iteration that may occur within the processes depicted in the ‘funnel’ and through preclinical models. Side bars indicate where additional insights are required to develop 
a robust case for progression of a vaccine through to licensure. These may be vaccine candidate agnostic or require insights specific to each candidate. The roadblocks identified at each 
stage are discussed further in the text. CHIM, controlled human infection model; cGMP, current Good Manufacturing Process; CMC, chemistry, manufacturing, and controls; IP, intellectual 
property; $, investment. (Original Figure) 
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2.3. Exploiting parasite genomics to further identify 
candidate antigens and mechanisms of protection
The Leishmania genome contains approximately 8500 genes, 
many encoding ‘hypothetical’ proteins of currently unknown 
function. Genome instability and aneuploidy, together with 
a sexual stage in the sand fly vector that facilitates the generation 
of ‘genetic hybrids’ [56,57] all serve to complicate Leishmania 
genetics. To date, our increased knowledge concerning genetic 
diversity in Leishmania has not been used to directly identify 
candidate vaccine antigens or novel mechanisms of immunity. 
The recently reported ability to generate hybrids in vitro may 
allow use of forward genetics to address these challenges [58]. As 
a result of polycistronic transcription, mRNA abundance in 
Leishmania is controlled by gene dosage [59] and post- 
transcriptionally and/or post-translationally [60]. Transcriptomic 
studies have identified stage-specific differences in mRNA abun-
dance, providing opportunities for reverse genetic approaches to 
identify candidate antigens associated with infective stages of 
the life cycle, e.g. through high throughput DNA vaccine screen-
ing [61]. The development of high throughput protein expres-
sion systems may also facilitate more rapid identification of 
candidate vaccine antigens [62]. Recently, application of micro-
bial genome-wide association studies (mGWAS) led to the iden-
tification of genetic markers associated with miltefosine 
resistance in Leishmania infantum [63] and similar approaches 
could be used to identify potential Leishmania vaccine candidate 
antigens, as mooted for other pathogens [64]. The full power of 
such approaches is only likely to be realized through application 
of knowledge on the epidemiology of disease in different geo-
graphic settings. This will require insights into parasite epide-
miology and transmission, information that will be equally 
valuable in the design of future clinical trials. The recent applica-
tion of CRISPR-cas9 technology in Leishmania provides opportu-
nities to introduce gene modifications/deletions creating 
parasite strains lacking specific antigens, a valuable tool to assess 
the importance of putative virulence factors and to formally 
distinguish between bystander and antigen-specific immunity 
following vaccination. In addition, CRISPR-cas9 underpins the 
development of live GA Leishmania vaccines [33].
Whilst immune mechanisms of protection may vary across 
the spectrum of leishmaniasis, a vaccine with prophylactic 
efficacy in at least most of the major forms of human disease 
would be more desirable than one restricted to a single dis-
ease entity. Hence, there is considerable value in incorporating 
antigens shared across parasite species and/or where HLA 
binding across diverse populations can be demonstrated. 
Cross-species sequence conservation is a criterion for selection 
of most subunit vaccines, perhaps exemplified by KMP-11 
[37,65], and is obviated in the case of a GA live vaccine. In 
some cases, sequencing of clinical isolates has been used to 
fine tune antigens to maximize their chances of immune 
recognition. For example, the gene encoding hydrophilic acy-
lated surface protein (HASP) B (as used in the ChAd63-KH 
vaccine) was engineered to produce a synthetic gene product 
in which the repeat regions retained the diversity and repeat 
structure found in isolates from across East Africa and 
India [65].
2.4. Appropriate use of preclinical and human models
Leishmania can infect and cause disease in a range of mam-
malian host, including mice, hamsters, guinea pigs, rats, and 
primates. Numerous reviews have provided in-depth evalua-
tion of some of the advantages as well as the limitations of 
various models used for the pre-clinical evaluation of vaccine 
candidates [66,67], and a recent review identified >160 vac-
cine studies in the literature using such pre-clinical models 
[68]. Most recently, some of these models, notably in mouse 
[31] and hamster [69], have been refined by the introduction 
of sand fly challenge, accommodating the view that vaccine- 
induced protection may differ between needle inoculation 
and natural challenge [70]. Whilst model refinement is likely 
to impact on their predictive efficacy, two limitations remain. 
First, despite intense study in rodents, understanding of the 
human response to infection remains somewhat limited, with 
many clinical studies remaining focused on a handful of car-
dinal cytokines associated with protective mechanism in leish-
maniasis, but which have been largely lacking in predictive 
power when applied to vaccine studies. A more unbiased 
evaluation of human immune responses would allow for 
a broader perspective on the similarities and differences asso-
ciated with each pre-clinical model. Deep phenotyping of 
Leishmania lesions using bulk or spatially resolved transcrip-
tomics/proteomics have been conducted [71–73] and given 
the relatively modest changes in clinical protocol or tissue 
sampling required for such studies, failure to expand this 
type of research represents a lost opportunity for the field. 
Analysis costs are of course not insignificant. Second, as well 
documented for other vaccines-preventable diseases, lessons 
learnt through clinical trial are essential for effective vaccine 
selection and development. This iterative cycle is at best 
rudimentary for leishmaniasis vaccines. There is an urgent 
need to enhance the throughput of early-stage trials to estab-
lish immunogenicity profiles in humans and associate these 
with outcomes e.g. skin test conversion in a prophylactic set-
ting, or clinical response in a therapeutic setting.
2.5. Advancing clinical trials
A search on clinicaltrials.gov (July 2021) using the terms 
‘malaria’ and ‘vaccine’ reveals 2 early-phase challenge studies, 
171 Phase I studies, 88 Phase II studies and 19 Phase III studies. 
In contrast, a similar search of ‘leishmaniasis’ and vaccine” 
yielded 9 Phase I (mostly polyprotein fusions vaccines), 7 
Phase II (two Alum-ALM+BCG, three ChAd63-KH and two 
with recombinant protein vaccines) and 2 phase III (both 
Alum-ALM+BCG). Only one study (NCT03969134) is currently 
recruiting. Whilst not suggesting that leishmaniasis vaccine 
R&D should be on par with that of malaria, these figures do 
nevertheless illustrate that based on the numbers of candi-
dates tested, the odds are currently stacked against discover-
ing a vaccine for leishmaniasis. Furthermore, the paucity of 
clinical trials of leishmaniasis vaccines negates iterative learn-
ing, of obvious benefit during malaria vaccine development. 
Failed clinical trials [74], if analyzed in depth, can provide vital 
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clues not only on what constitutes a correlate of protection 
but also what does not.
The reasons behind the paucity of clinical trials of leishma-
niasis vaccines is not for want of candidates, but the combined 
effects of lack of funding, lack of commercial incentive and 
clearly defined public health value, poorly predictive models 
and a reluctance on the part of many researchers to embark 
on a road so fraught with uncertainty [30,39,75,76]. G-Finder 
data (https://gfinderdata.policycuresresearch.org/pages/data- 
visualisations/allNeglectedDiseases) indicates a drop in overall 
funding for leishmaniasis from 2% of total global R&D spend 
in 2007–2012 to only 1% from 2013 − 2019 (not including core 
funding for research organizations involved in leishmaniasis 
control) with a marked decline in investment from ~60-80 M p. 
a. in 2007–2010 to almost level funding of $45 M from 2012 
onwards ($41 M in 2019). Since 2007, approx. $79 M was 
earmarked specifically as vaccine research (~12%). In contrast, 
over the same period drug development received ~ $223 M 
(33%). Hence, even within funding dedicated to leishmaniasis, 
vaccine development is apparently not highly prioritized by 
funders. There may be many factors accounting for this, 
including proven past successes and the effectiveness of 
a structured approach to drug development facilitated by 
DNDi and greater investment in drug discovery infrastructure 
for neglected diseases e.g. the Tres Cantos Open Lab 
Foundat ion  (ht tps : / /www.openlabfoundat ion .org/  
AboutTheOpenLab) established by GSK and the Novartis 
Institute for Tropical Diseases (https://www.novartis.com/our- 
science/novartis-institutes-biomedical-research/research- 
locations/novartis-institute-tropical). Furthermore, vaccine 
development remains a highly risky enterprise with a much 
lower expected return than drug development, especially for 
oncology and rare diseases with their high prices. This is even 
more true for diseases primarily affecting low-income settings. 
As a result, private funding (in particular venture capital, often 
critical for the transition into clinical development) is even 
more rarely directed toward those vaccines.
As discussed below, reaping the benefits of discovery 
science for vaccine development will require targeted research 
aimed at building a public health and commercial value pro-
position to support the investment needed to redress this 
imbalance. Our own experience has been that ~$2 M was 
sufficient to develop a new candidate vaccine from concep-
tion through to completion of a first-in-human trial. If com-
bined with human infection models [77,78,79] (and Parkash 
et al., this volume), we estimate that efficacy data on similar 
new vaccines could be achieved for a total development cost 
of under $4 M. Relative to the investment in vaccine antigen 
selection and other aspects of discovery research, this appears 
a rather modest sum. The leishmaniasis vaccine research 
development community should raise the bar and set an 
ambition for at least one new candidate vaccine to enter 
clinical development every other year. We should take advan-
tage of investments being made in vaccine manufacturing 
infrastructure for example by UK Research and Innovation 
[80] and align our plans to benefit from such resources. 
Should more than one vaccine candidate prove safe and 
immunogenic in first-in-human trials, well-designed adaptive 
trials should be employed in controlled human infection 
models and/or Phase II clinical trials to allow comparability 
of performance and ease of down-selection.
2.6. Modeling the impact of vaccines
Unsurprisingly, the epidemiology of leishmaniasis is complex 
and varied, particularly so for VL where epidemic cycles are 
the norm. Mathematical models have played an important role 
in underpinning strategies for the control of NTDs [81] includ-
ing the campaign to eliminate VL from the Asian sub- 
continent [82]. Most research has focused on improving 
understanding of transmission dynamics for example on 
a regional scale as for VL in the Indian subcontinent [83], to 
monitor outbreaks or to assess different transmission modes 
[84]. More recently, spatio-temporal models have been devel-
oped focusing on household or community data [85–87] high-
lighting the heterogeneity of disease incidence and 
transmission. In contrast, few studies have used epidemiologi-
cal modeling to predict how vaccines may serve as effective 
public health measures. For canine VL, models have been used 
to illustrate the potential of vaccines to reduce the basic 
reproductive rate (R0) [88,89]. In our recent work [90], we 
used a set of age-structured deterministic models of VL 
(Erasmus MC) parameterized with data from Bihar, India [91] 
to evaluate the degree to which vaccination could provide an 
additional tool for VL elimination in South Asia. We simulated 
introduction of vaccines with a variety of different character-
istics and found that those which prevented the development 
of clinical VL, or reduced host infectiousness were likely to 
have most significant impact. In addition, we found that 
a vaccine which prevented the development of PKDL would 
be highly effective at sustaining the VL elimination target once 
reached through existing control measures, supporting data 
from spatio-temporal modeling that also suggests PKDL 
patients play a significant role in VL transmission [92].
Further studies of this type, using spatio-temporal models 
that allow assessment of the impact of vaccines targeting 
different aspects of disease natural history, deployed with 
different schedules and with differing efficacy are urgently 
needed. In addition, expanding the modeling of other forms 
of leishmaniasis including zoonotic cutaneous leishmaniasis 
[93,94] should be seen as a priority, so that the potential 
global impact of newly developed vaccines might be more 
fully assessed.
Molecular epidemiology encompassing both parasite and 
host is also likely to be of increasing importance in designing 
appropriate early and late phase clinical trials. We currently do 
not fully understand what dictates variability in clinical cure 
rates and the potential impact of co-infections, nutritional 
status or environmental factors on vaccine responsiveness. 
Biomarkers of disease outcome and treatment response have 
been developed based on whole-blood transcriptional signa-
tures [95] and similar approaches may provide new tools for 
monitoring therapeutic vaccine responses. We recently identi-
fied a myeloid cell associated gene signature associated with 
early cure in a small cohort of patients with persistent PKDL in 
Sudan, though whether this reflects a response to vaccination 
or provides an insight into the immune status of patients likely 
to self-cure remains an open question [39]. Parasite 
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genotyping will likely play an important role in clinical trial 
design, allowing stratification of patients based on parasite 
genotype and avoiding confounding issues related, for exam-
ple, to the presence of genetic hybrids.
2.7. Identifying vaccine demand
It is commonplace to present leishmaniasis as a disease wait-
ing for a vaccine, built on the argument that vaccination is an 
achievable goal when seen from an immunological perspec-
tive [75]. Whilst this is the case, it represents only half of the 
argument when considering vaccine development. To fully 
justify this standpoint also requires an understanding of 
demand, largely reflecting target population size, schedule of 
immunizations, roll out approach, longevity of protection and 
frequency of booster vaccinations. Many of these factors are 
also reflected in the target product profile (TPP) and have 
repercussions for choice of vaccine delivery platform, manu-
facturing approaches and scalability and lead through to the 
design of early phase clinical studies. Although there have 
been attempts to formulate a TPP for a visceral leishmaniasis 
vaccine [96], there have been no substantive attempts to 
model demand, despite the proven usefulness of this 
approach in the development of rotavirus and pneumococcal 
vaccines [97]. This gap is also the result of the absence of an 
agreed, ideally WHO sanctioned global view, and conse-
quently estimate, of the size of the population at risk of 
leishmaniasis (both VL and CL). Thus the size of the problem 
remains unknown.
As a start to addressing this roadblock, we recently devel-
oped an in-depth demand forecast for human leishmaniasis 
vaccines [98]. The approach taken was vaccine-agnostic and 
examined demand for specific ‘use cases,’ namely prophylaxis 
targeting either VL, CL or both, and/or therapeutic targeting 
PKDL. As neither the efficacy nor the required schedule for 
a vaccine has yet to be established, we modeled a range of 
potential scenarios each involving roll out initiated with 
a catch-up campaign but ranging from population coverage 
in regions at risk with multiple booster vaccinations, to more 
targeted vaccination campaigns using a more limited vaccina-
tion schedule. In each setting, we factored into the simulation 
the population at risk and their evolving demographics, allow-
ing for a final determination of demand based on the number 
of doses required. Not surprisingly given the paucity of data 
and the uncertainty surrounding some of our assumptions, 
estimates of demand varied under different simulations con-
ditions, from 310 million to 830 million doses required for 
preventing VL and from 557 million to 1400 million doses 
required for preventing CL, over a 10-year period (2030– 
2040). If a stand-alone vaccine was required for targeting 
PKDL (i.e. vaccines preventing clinical VL did not prevent 
PKDL), such a vaccine might have more limited demand (~ 
330,000 doses over 10 years). These initial results would sug-
gest sufficient demand to support commercial manufacture of 
prophylactic vaccines targeting CL and/or VL, whereas the 
limited demand for a vaccine to prevent or treat PKDL might 
favor philanthropic donors or the use of development path-
ways favoring orphan indications [98]. Similar considerations 
regarding limited demand may also come into play when 
considering the development of vaccines where protection 
might be confined (e.g. by the nature of the vaccine compo-
nents) to specific forms of CL, hence targeting only a region- 
specific portion of the global population at risk. Conversely, 
should a vaccine be also protective in canids, overall demand 
estimates (and affordability, see below) might increase, at least 
for countries where zoonotic VL predominates.
Models of this type can help early-stage vaccine develop-
ment gain an awareness of the impact of, for example, differ-
ing vaccination schedules and to factor this into early-stage 
vaccine design. However, the future refinement of such mod-
els will be dependent on access to more nuanced data on the 
population at risk for the various leishmaniases, and hence 
would require significantly improved modeling of disease 
transmission and the ability to evaluate vaccine impacts 
when deployed in different ways (e.g. ring vaccination as 
a means of outbreak prevention).
2.8. Understanding the affordability (or ability to pay 
for) of vaccines
Complementary to an understanding of likely demand for 
a leishmaniasis vaccine, is an assessment of different countries’ 
health systems abilities to pay for such vaccines, regardless of 
whether this is funded entirely through domestic sources or 
with support from international funders. All countries have 
limited resources with which to meet the health needs of 
their populations. It is, therefore, crucial to know whether mak-
ing funding available for the purchase and deployment of 
leishmaniasis vaccines would generate a positive or negative 
impact on the health of the population when compared with 
other claims upon limited resources. Cost-effectiveness analysis 
(CEA) can inform this assessment and is widely used in many 
areas of health care, including for vaccines, such as Human 
Papilloma virus, Chagas disease, norovirus, and influenza 
[99,100]. It requires estimation of the health effects of vaccines 
(for instance, as measured by DALY’s averted), the full commod-
ity and delivery cost net of resource savings generated by 
avoiding cases of disease. When there is an additional net cost 
imposed on the health system through acquisition of the vac-
cine, it is necessary also to know what health gains could have 
been generated if the equivalent of that net cost was to be 
invested in other interventions and programs (i.e. the health 
opportunity cost). This can be expressed as a ‘cost-effectiveness 
threshold’ reflecting the system’s marginal productivity and 
hence ability to pay [101].
Studies providing estimates for the cost-effectiveness of 
leishmaniasis vaccines are few. Lee et al. [102] used a Markov 
modeling approach to generate an estimate of cost- 
effectiveness for a vaccine targeting VL in Bihar state, India. 
Their analysis, based on 2012 data on VL incidence and treat-
ment costs (including for Amphotericin B, hospitalization, loss 
of earnings etc.), suggested that a vaccine with >50% efficacy 
would be cost-effective at a vaccination cost (including vac-
cine components, accessories, storage, distribution, labor, and 
training) per individual of $350 and one with 25% efficacy 
would still be cost-effective at $100. However, this study did 
not take into account the practical considerations of vaccine 
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introduction, such as gradual rollout and wastage. Further, it 
relied upon very high assessments of how much countries 
could afford to pay, based upon now discredited former 
WHO guidance of using a cost-effectiveness threshold equal 
to a country’s Gross Domestic Product per capita [103] rather 
than the health system’s ability to pay.
More recently, we have projected the economic feasibility 
of a leishmaniasis vaccine based on estimates of cost- 
effectiveness thresholds reflecting health opportunity costs, 
as well as disease incidence and burden of disease [104]. In 
contrast to the approach taken by Lee et al., our simulation 
projects the future value of the vaccine based on a realistic 
timescale of availability and distribution, accounts for time-
scales of vaccine rollout and changes in health systems and is 
an estimate of the full health system cost per vaccinated 
individual that countries can afford [104]. Given current esti-
mates of population at risk, this analysis suggests that for 13 
out of the 24 countries (representing 80% of the global bur-
den of CL and VL) which were analyzed, the projected demand 
for vaccines between 2030 and 2040 could be afforded at 
vaccination costs over $3 per course administered under cost- 
effectiveness considerations, even if the efficacy of the vaccine 
were as low as 50%. Given the expected manufacturing costs 
of $2-3, at least for some candidate vaccines with production 
at scale [105], this implies that the vaccine would be commer-
cially viable, unless the vaccine implementation costs are pro-
hibitive. Furthermore, these calculations may under-estimate 
significantly the ability to pay due to a number of factors, 
notably exclusion of vaccine impacts on transmission 
[106,107], under-reporting of disease incidence [5,108], under- 
appreciation of disease burden [5] and treatments costs due 
to HIV co-infection [109].
Capturing a vaccine’s potential economic value as 
described above will also provide valuable insights spanning 
the development process and that can be used to inform the 
development of TPPs, including generating estimates of man-
ufacturing scale and costs, efficacy targets, refining target 
populations, and target demand.
2.9. Increasing advocacy for leishmaniasis vaccines
Numerous examples exist where the R&D and public health 
and financial communities have come together to facilitate 
change in the vaccine or drug development landscape 
through product development partnerships (PDPs) 
Notable examples include the Medicines for Malaria 
Venture (https://www.mmv.org), the TB Alliance (https:// 
www.tballiance.org) and the International AIDS Vaccine 
Initiative (https://www.iavi.org). Unlike these PDPs that 
focus on a single disease, the Drugs for Neglected 
Diseases Initiative (DNDi) takes a somewhat broader 
approach and has been spectacularly successful, delivering 
eight new treatments for five neglected tropical diseases. 
For leishmaniasis, DNDi have supported the introduction of 
two new treatments for VL and currently have seven new 
chemical entities under development (one preclinical, five 
in Phase I and one in proof of concept). Likewise, the 
European Vaccine Initiative (EVI) (https://www.euvaccine. 
eu) promotes vaccine R&D and supports clinical develop-
ment of vaccines for malaria, leishmaniasis, Shigella, Nipah, 
and Zika viruses, as well as more recently COVID-19. In 
addition, EVI supports cross-cutting platforms providing 
important resources for the vaccine community, including 
coordinating access to critical EU-funded infrastructure for 
clinical trials (TRANSVAC2: https://www.transvac.org/trans 
vac2). Thus, through EVI a framework may already exist 
to expand advocacy for leishmaniasis vaccine development 
without the burden of establishing a new entity.
The importance of making meaningful progress toward 
‘joining the dots’ across these diverse aspects of the vac-
cine development process has been similarly articulated by 
Hotez and colleagues in their broader ‘call for action’ for 
NTD vaccines [76]. The recent pandemic of SARS-CoV-2 has 
highlighted how research communities nationally and 
internationally can be brought together to achieve unpre-
cedented gains in terms of both fundamental knowledge 
and translational impact. For small research communities 
already hampered by fragmentation and limited resources, 
such as those engaged in leishmaniasis vaccine develop-
ment, this must provide a lesson on how future progress 
can be made to overcome the roadblocks of the past.
3. Expert opinion
Developing new measures to control leishmaniasis remains 
as important as ever. In drug development, DNDi has 
helped established a robust pipeline of preclinical candi-
dates and a clear pathway for translational development 
(https://dndi.org/research-development/portfolio). Whilst 
the former is also true of vaccine discovery research, the 
latter is sorely missing. For vaccines against leishmaniasis 
to become a reality, previous roadblocks need to be over-
come, through increasing collaborative working, the devel-
opment of shared resources and harmonized approaches 
to preclinical and clinical evaluation and a commitment to 
the use of innovative cost-effective clinical trials coupled 
with state-of-the-art approaches to identify potential cor-
relates of vaccine-induced immunity. The vaccine R&D pro-
cess needs to be supported and informed by the greater 
use of epidemiological modeling to evaluate the true bur-
den of disease and size of the population at risk, predict 
the benefits of vaccines in different disease settings and 
through the application of economic modeling to ensure 
vaccines being developed are suitable for and will be used 
by the desired market. On this basis, realistic estimates of 
demand need to be continuously updated to inform deci-
sions of vaccine developers and ministers of health. These 
goals are challenging, but by taking the first steps toward 
developing a shared collective ambition, the research com-
munity may generate sufficient leverage to stimulate 
greater funder awareness of the progress made and the 
potential public health benefits of vaccination and help 
secure delivery of the first registered vaccine for human 
leishmaniasis.
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Though prophylactic vaccines may provide maximal 
public health benefit, the role of therapeutic vaccines, 
used alone or in combined immune-chemotherapy, should 
not be ignored and progress here may be facilitated by 
greater integration of drug and vaccine development.
If successful, over the next five years researchers at the fore 
of human and veterinary vaccine development will have 
taken the first steps to developing a collaborative network 
showcasing developments in the field of leishmaniasis vacci-
nology and the evidence-base supporting the argument for 
vaccine manufacture and clinical evaluation as well as for 
country adoption. They will continue to feed the pipeline of 
vaccine candidates through discovery research that exploits 
cutting-edge multi-omics approaches to studying parasite 
biology and disease pathogenesis in humans and animal 
models. There will be established means to efficiently test 
such candidates in validated preclinical models utilizing 
diverse delivery systems (mRNA, viral vectors, adjuvanted 
protein), and a critical and robust approach to vaccine down- 
selection based on an expanded portfolio of human infection 
models. Funding for leishmaniasis vaccine development will 
be sought not in a piecemeal manner, where the likelihood of 
return is low, but through longer and larger awards. These will 
support a collective interdisciplinary vision that is cognisant 
of the role that vaccines play in a broader ‘one health’ solu-
tion to the challenges posed by leishmaniasis. Within 5 years, 
safety, immunogenicity and initial efficacy data should have 
been obtained for at least two vaccines, and up to three new 
candidates will have moved toward clinical development, as 
a mark of renewed commitment and ambition.
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